Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry

Donghui Bao, Thanh Thai Truong, Paul J. Renick, Mark E. Pulse, William Weiss

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of this study was to develop a specific and sensitive liquid chromatography mass spectrometry (LC/MS) method for the determination of rifampicin and levofloxacin concentrations from infected tissues within teflon catheter segments which were subcutaneously implanted in mice. A solid-phase extraction procedure was used to extract analytes from tissue homogenates of the catheter segments and reverse-phase HPLC combined with positive electrospray ionization mass spectrometry was used for analyte separation and quantification. The assay was found to be linear over the concentration range of 0.02-2 μg/g for rifampicin and levofloxacin in tissues and provided good validation data for accuracy and precision. The intra-day accuracy as determined by the relative error was -1.3% for levofloxacin and 6.1% for rifampicin, and precision was evaluated by R.S.D.s with a maximum of 5.1% for levofloxacin and 8.1% for rifampicin. The inter-day accuracy was -3.3% for levofloxacin and -4.6% for rifampicin, and precision was 8.6% for levofloxacin and 7.1% for rifampicin. The assay uses less tissue than previously described methods and can be applied to determine the penetration of rifampicin and the fluoroquinolone in catheter segments from a mouse model of a device-related infection. Finally, the HPLC-MS assay should be applicable to studies of rifamycin + quinolone combination therapies in other animal models of bacterial infection.

Original languageEnglish
Pages (from-to)723-727
Number of pages5
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume46
Issue number4
DOIs
StatePublished - 13 Mar 2008

Fingerprint

Electrospray ionization
Levofloxacin
Electrospray Ionization Mass Spectrometry
Catheters
Liquid chromatography
Rifampin
Tandem Mass Spectrometry
Liquid Chromatography
Mass spectrometry
Equipment and Supplies
Infection
Assays
Tissue
High Pressure Liquid Chromatography
Tissue Extracts
Quinolones
Fluoroquinolones
Solid Phase Extraction
Polytetrafluoroethylene
Bacterial Infections

Keywords

  • Catheter
  • Device-related infections
  • LC/MS
  • Levofloxacin
  • Rifampicin

Cite this

@article{f7b204ebd2864c5f899ecb8aad8acaf2,
title = "Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry",
abstract = "The aim of this study was to develop a specific and sensitive liquid chromatography mass spectrometry (LC/MS) method for the determination of rifampicin and levofloxacin concentrations from infected tissues within teflon catheter segments which were subcutaneously implanted in mice. A solid-phase extraction procedure was used to extract analytes from tissue homogenates of the catheter segments and reverse-phase HPLC combined with positive electrospray ionization mass spectrometry was used for analyte separation and quantification. The assay was found to be linear over the concentration range of 0.02-2 μg/g for rifampicin and levofloxacin in tissues and provided good validation data for accuracy and precision. The intra-day accuracy as determined by the relative error was -1.3{\%} for levofloxacin and 6.1{\%} for rifampicin, and precision was evaluated by R.S.D.s with a maximum of 5.1{\%} for levofloxacin and 8.1{\%} for rifampicin. The inter-day accuracy was -3.3{\%} for levofloxacin and -4.6{\%} for rifampicin, and precision was 8.6{\%} for levofloxacin and 7.1{\%} for rifampicin. The assay uses less tissue than previously described methods and can be applied to determine the penetration of rifampicin and the fluoroquinolone in catheter segments from a mouse model of a device-related infection. Finally, the HPLC-MS assay should be applicable to studies of rifamycin + quinolone combination therapies in other animal models of bacterial infection.",
keywords = "Catheter, Device-related infections, LC/MS, Levofloxacin, Rifampicin",
author = "Donghui Bao and Truong, {Thanh Thai} and Renick, {Paul J.} and Pulse, {Mark E.} and William Weiss",
year = "2008",
month = "3",
day = "13",
doi = "10.1016/j.jpba.2007.11.023",
language = "English",
volume = "46",
pages = "723--727",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry

AU - Bao, Donghui

AU - Truong, Thanh Thai

AU - Renick, Paul J.

AU - Pulse, Mark E.

AU - Weiss, William

PY - 2008/3/13

Y1 - 2008/3/13

N2 - The aim of this study was to develop a specific and sensitive liquid chromatography mass spectrometry (LC/MS) method for the determination of rifampicin and levofloxacin concentrations from infected tissues within teflon catheter segments which were subcutaneously implanted in mice. A solid-phase extraction procedure was used to extract analytes from tissue homogenates of the catheter segments and reverse-phase HPLC combined with positive electrospray ionization mass spectrometry was used for analyte separation and quantification. The assay was found to be linear over the concentration range of 0.02-2 μg/g for rifampicin and levofloxacin in tissues and provided good validation data for accuracy and precision. The intra-day accuracy as determined by the relative error was -1.3% for levofloxacin and 6.1% for rifampicin, and precision was evaluated by R.S.D.s with a maximum of 5.1% for levofloxacin and 8.1% for rifampicin. The inter-day accuracy was -3.3% for levofloxacin and -4.6% for rifampicin, and precision was 8.6% for levofloxacin and 7.1% for rifampicin. The assay uses less tissue than previously described methods and can be applied to determine the penetration of rifampicin and the fluoroquinolone in catheter segments from a mouse model of a device-related infection. Finally, the HPLC-MS assay should be applicable to studies of rifamycin + quinolone combination therapies in other animal models of bacterial infection.

AB - The aim of this study was to develop a specific and sensitive liquid chromatography mass spectrometry (LC/MS) method for the determination of rifampicin and levofloxacin concentrations from infected tissues within teflon catheter segments which were subcutaneously implanted in mice. A solid-phase extraction procedure was used to extract analytes from tissue homogenates of the catheter segments and reverse-phase HPLC combined with positive electrospray ionization mass spectrometry was used for analyte separation and quantification. The assay was found to be linear over the concentration range of 0.02-2 μg/g for rifampicin and levofloxacin in tissues and provided good validation data for accuracy and precision. The intra-day accuracy as determined by the relative error was -1.3% for levofloxacin and 6.1% for rifampicin, and precision was evaluated by R.S.D.s with a maximum of 5.1% for levofloxacin and 8.1% for rifampicin. The inter-day accuracy was -3.3% for levofloxacin and -4.6% for rifampicin, and precision was 8.6% for levofloxacin and 7.1% for rifampicin. The assay uses less tissue than previously described methods and can be applied to determine the penetration of rifampicin and the fluoroquinolone in catheter segments from a mouse model of a device-related infection. Finally, the HPLC-MS assay should be applicable to studies of rifamycin + quinolone combination therapies in other animal models of bacterial infection.

KW - Catheter

KW - Device-related infections

KW - LC/MS

KW - Levofloxacin

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=39149141361&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2007.11.023

DO - 10.1016/j.jpba.2007.11.023

M3 - Article

C2 - 18178051

AN - SCOPUS:39149141361

VL - 46

SP - 723

EP - 727

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 4

ER -